PT - JOURNAL ARTICLE AU - A D Singh AU - C J Sanderson TI - Anti-interleukin 5 strategies as a potential treatment for asthma. AID - 10.1136/thx.52.5.483 DP - 1997 May 01 TA - Thorax PG - 483--485 VI - 52 IP - 5 4099 - http://thorax.bmj.com/content/52/5/483.short 4100 - http://thorax.bmj.com/content/52/5/483.full SO - Thorax1997 May 01; 52 AB - A paradigm shift, championed largely by cellular immunologists, has redefined asthma as an immune mediated phenomenon characterised by an interleukin 5 (IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense interest in the possibility that inhibitors of IL-5 production, or antagonists of its activity, will provide a new generation of anti-asthma drugs.